Skip to main content

Table 1 Overall characteristics of 143 ER+/HER2- breast cancer patients without distant metastases

From: 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

  No. of patients (%)
Age in years
mean (SD), median [min, max] 51.4 (11.4), 50 [30; 78]
Histological type
 Invasive ductal carcinoma 129 (90%)
 Lobular 7 (5%)
 Other 7 (5%)
Grade
 Grade 1 7 (5%)
 Grade 2 91 (64%)
 Grade 3 42 (29%)
 Grade unknown 3 (2%)
Progesterone receptor expression
 Negative 55 (38%)
 Positive 88 (62%)
Tumor classificationa
 T1 3 (2%)
 T2 53 (37%)
 T3 56 (39%)
 T4 31 (22%)
Lymph node classificationa
 N0 58 (40%)
 N1 71 (50%)
 N2 11 (8%)
 N3 3 (2%)
Stagea
 Stage IIA 25 (18%)
 Stage IIB 49 (34%)
 Stage IIIA 36 (25%)
 Stage IIIB 30 (21%)
 Stage IIIC 3 (2%)
  1. ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor 2-negative, SD standard deviation
  2. aClinical classification and stage after the clinical examination and before 18F-FDG-PET/CT according to the seventh edition of the AJCC Cancer Staging Manual